down arrow

Nevro Corp.

  • Market Cap: Micro Cap
  • Industry: Medical Specialties
  • ISIN: US64157F1030
USD
5.84
0.00 (0.00%)

Apr 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

3.176.72
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Dec 2024)

FII

15.12%

Held by 104 FIIs

DII

45.15%

Held by 44 DIIs

Promoter

0.03%

How big is Nevro Corp.?

22-Jun-2025

As of Apr 04, Nevro Corp. has a market capitalization of 221.08 million and reported net sales of 408.52 million with a net profit of -113.43 million. The company has shareholder's funds of 231.01 million and total assets of 553.84 million as of Dec'24.

As of Apr 04, Nevro Corp. has a market capitalization of 221.08 million, classified as a Micro Cap.<BR><BR>As of the latest four quarters, Nevro Corp. reported net sales of 408.52 million and a net profit of -113.43 million.<BR><BR>As of Dec'24, the company has shareholder's funds amounting to 231.01 million and total assets of 553.84 million.

Read More

What does Nevro Corp. do?

22-Jun-2025

Nevro Corp. is a global medical device company focused on improving the quality of life for chronic pain patients. As of December 2024, it reported net sales of $106 million and a net loss of $53 million, with a market cap of $221.08 million.

Overview:<BR>Nevro Corp. is a global medical device company that focuses on providing products to improve the quality of life for patients suffering from chronic pain, operating within the Medical Specialties industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 106 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -53 Million (Quarterly Results - Dec 2024) <BR>Market-cap: USD 221.08 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 95.58% <BR>Debt Equity: -0.29 <BR>Return on Equity: -47.53% <BR>Price to Book: 0.96<BR><BR>Contact Details:<BR>Address: 1800 Bridge Pkwy, REDWOOD CITY CA: 94065-1164 <BR>Tel: ['1 650 2510005', '1 650 4333247'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.nevro.com

Read More

Who are in the management team of Nevro Corp.?

22-Jun-2025

As of March 2022, the management team of Nevro Corp. includes D. Keith Grossman (Chairman, President, CEO), Michael DeMane (Lead Independent Director), and Directors Susan Siegel, Frank Fischer, Shawn McCormick, and Kevin O'Boyle.

As of March 2022, the management team of Nevro Corp. includes the following individuals:<BR><BR>- Mr. D. Keith Grossman, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Mr. Michael DeMane, who is the Lead Independent Director.<BR>- Ms. Susan Siegel, who is a Director.<BR>- Mr. Frank Fischer, who is an Independent Director.<BR>- Mr. Shawn McCormick, who is also an Independent Director.<BR>- Mr. Kevin O'Boyle, who serves as an Independent Director.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

USD 221 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

95.58%

stock-summary
Debt Equity

-0.29

stock-summary
Return on Equity

-47.53%

stock-summary
Price to Book

0.96

Revenue and Profits:
Net Sales:
106 Million
(Quarterly Results - Dec 2024)
Net Profit:
-53 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
57.41%
0%
57.41%
6 Months
17.51%
0%
17.51%
1 Year
-55.79%
0%
-55.79%
2 Years
-83.54%
0%
-83.54%
3 Years
-92.33%
0%
-92.33%
4 Years
-95.89%
0%
-95.89%
5 Years
-93.78%
0%
-93.78%

Nevro Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.92%
EBIT Growth (5y)
0.37%
EBIT to Interest (avg)
-7.75
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.84
Tax Ratio
0.97%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.96
EV to EBIT
-1.63
EV to EBITDA
-1.92
EV to Capital Employed
0.94
EV to Sales
0.38
PEG Ratio
NA
Dividend Yield
95.58%
ROCE (Latest)
-57.59%
ROE (Latest)
-47.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 50 Schemes (39.7%)

Foreign Institutions

Held by 104 Foreign Institutions (15.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is -9.21% vs 2.11% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is -490.00% vs 53.12% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105.50",
          "val2": "116.20",
          "chgp": "-9.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.70",
          "val2": "-8.80",
          "chgp": "-123.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.60",
          "val2": "3.20",
          "chgp": "106.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.00",
          "val2": "-4.10",
          "chgp": "-558.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-53.10",
          "val2": "-9.00",
          "chgp": "-490.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-217.90%",
          "val2": "-101.50%",
          "chgp": "-11.64%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -3.93% vs 4.63% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -22.99% vs -3,173.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "408.50",
          "val2": "425.20",
          "chgp": "-3.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-80.60",
          "val2": "-87.80",
          "chgp": "8.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "26.90",
          "val2": "8.00",
          "chgp": "236.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.60",
          "val2": "-4.10",
          "chgp": "12.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-113.40",
          "val2": "-92.20",
          "chgp": "-22.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-231.80%",
          "val2": "-233.60%",
          "chgp": "0.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - YoYstock-summary
Dec'24
Dec'23
Change(%)
Net Sales
105.50
116.20
-9.21%
Operating Profit (PBDIT) excl Other Income
-19.70
-8.80
-123.86%
Interest
6.60
3.20
106.25%
Exceptional Items
-27.00
-4.10
-558.54%
Consolidate Net Profit
-53.10
-9.00
-490.00%
Operating Profit Margin (Excl OI)
-217.90%
-101.50%
-11.64%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2024 is -9.21% vs 2.11% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2024 is -490.00% vs 53.12% in Dec 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
408.50
425.20
-3.93%
Operating Profit (PBDIT) excl Other Income
-80.60
-87.80
8.20%
Interest
26.90
8.00
236.25%
Exceptional Items
-3.60
-4.10
12.20%
Consolidate Net Profit
-113.40
-92.20
-22.99%
Operating Profit Margin (Excl OI)
-231.80%
-233.60%
0.18%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -3.93% vs 4.63% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -22.99% vs -3,173.33% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Nevro Corp. stock-summary
stock-summary
Nevro Corp.
Medical Specialties
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
Company Coordinates stock-summary
Company Details
1800 Bridge Pkwy , REDWOOD CITY CA : 94065-1164
stock-summary
Tel: 1 650 25100051 650 4333247
stock-summary
https://www.nevro.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."